Related Experiment Video
Updated: Dec 31, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Current Therapeutic Strategies for Glioblastoma
Julien Rossignol1,2,3, Bhairavi Srinageshwar1,2,3, Gary L Dunbar1,2,4,5
1Field Neurosciences Institute laboratory for Restorative Neurology at Central Michigan University, Mt. Pleasant, MI 48859, USA.
Abstract:
Glioblastomas (GB) are grade 4 brain tumors, one of the most aggressive forms of brain cancer found in humans. Although current treatments for GB are largely ineffective, new alternate approaches, beyond standard chemo- or radiation therapies have shown promising results in both pre-clinical and clinical settings. Some of these approaches include stem cell therapy, new pharmaceuticals and nutraceuticals, and the use of tumor specific peptides or GB-targeted antibodies and immune-based therapies. A common limitation in the efficacy of these treatments is the inability of these therapeutic agents to readily cross the blood-brain barrier (BBB) to reach the tumor site. Therefore, many strategies are being developed to achieve targeted delivery of drugs across the BBB so that they can kill the cancer cells, while sparing healthy tissue. One of the most promising new approaches involves the use of nanoparticles that can carry therapeutic drugs and genes across the BBB and home in on the GB tumor site.
Insights
Glioblastoma (GB) is an aggressive brain cancer. Nanoparticles offer a promising strategy to overcome the blood-brain barrier (BBB) for targeted GB treatment delivery.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Drug Delivery
Background:
- Glioblastomas (GB) are aggressive grade 4 brain tumors with limited treatment efficacy.
- Current therapies face challenges in crossing the blood-brain barrier (BBB) to reach tumor sites.
- Emerging treatments include stem cells, pharmaceuticals, nutraceuticals, targeted peptides, antibodies, and immunotherapy.
Discussion:
- The primary challenge for effective glioblastoma treatment is delivering therapeutic agents across the BBB.
- Strategies focus on targeted drug delivery to maximize efficacy and minimize damage to healthy brain tissue.
- Nanoparticle-based drug delivery systems show significant potential for overcoming BBB limitations.
Key Insights:
- Nanoparticles can be engineered to transport therapeutic drugs and genes across the BBB.
- These nanoparticles can be designed to specifically target and home in on glioblastoma tumor sites.
- This targeted delivery mechanism enhances the potential for effective glioblastoma eradication.
Outlook:
- Further research into nanoparticle design and targeting mechanisms is crucial.
- Clinical translation of nanoparticle-based therapies could revolutionize glioblastoma treatment.
- Optimizing nanoparticle delivery systems will be key to improving patient outcomes for brain cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy